Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 303, Issue 6, 2012, Pages

  Xu, Xiangbin ^a   Ding, Fan ^a   Pang, Jinjiang ^a   Gao, Xue ^a   Xu, Rong Kun ^a   Hao, Wei ^a   Cao, Ji Min ^a   Chen, Chen ^b  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cardiac fibrosis; Collagen; Growth hormone secretagogue receptors; Matrix metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATINASE A; GELATINASE B; GROWTH HORMONE SECRETAGOGUE RECEPTOR; HEXARELIN; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; HYDROXYPROLINE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE FIBROSIS; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; COLLAGEN TYPE I; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION; HEART DISEASES; HYDROXYPROLINE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDIUM; OLIGOPEPTIDES; RATS; RATS, INBRED SHR; RATS, WISTAR; RECEPTORS, GHRELIN; RNA, MESSENGER; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84866416553     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00257.2011     Document Type: Article

References (43)

1. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 31: 988-998, 2000.
2. Bell D, Kelso EJ, Argent CC, Lee GR, Allen AR, McDermott BJ. Temporal characteristics of cardiomyocyte hypertrophy in the spontaneously hypertensive rat. Cardiovasc Pathol 13: 71-78, 2004.
3. Bish LT, Yarchoan M, Sleeper MM, Gazzara JA, Morine KJ, Acosta P, Barton ER, Sweeney HL. Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PLos One 6: e20856, 2011.
4. Bishop JE, Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Res 42: 27-44, 1999.
5. Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 90: 844-849, 2002.
6. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477: 267-283, 2000.
7. Chaswal M, Das S, Prasad J, Katyal A, Fahim M. Cardiac autonomic function in acutely nitric oxide deficient hypertensive rats: role of the sympathetic nervous system and oxidative stress. Can J Physiol Pharmacol 2011.
8. Cicogna AC, Brooks WW, Hayes JA, Robinson KG, Sen S, Conrad CH, Bing OH. Effect of chronic colchicine administration on the myocardium of the aging spontaneously hypertensive rat. Mol Cell Biochem 166: 45-54, 1997.
9. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, Raizada MK. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96: 287-294, 2011.
10. Iwase M, Kanazawa H, Kato Y, Nishizawa T, Somura F, Ishiki R, Nagata K, Hashimoto K, Takagi K, Izawa H, Yokota M. Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamsters. Cardiovasc Res 61: 30-38, 2004.
11. Janicki JS, Brower GL, Henegar JR, Wang L. Ventricular remodeling in heart failure: the role of myocardial collagen. Adv Exp Med Biol 382: 239-245, 1995.
12. Li H, Simon H, Bocan TM, Peterson JT. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE-and MMP-inhibition. Cardiovasc Res 46: 298-306, 2000.
13. Lijnen PJ, Petrov VV, Fagard RH. Induction of cardiac fibrosis by angiotensin II. Methods Find Exp Clin Pharmacol 22: 709-723, 2000.
14. 1. Mol Genet Metab 71: 418-435, 2000.
15. Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, Deghenghi R, Muller EE, Berti F. Growth hormoneindependent cardioprotective effects of hexarelin in the rat. Endocrinology 140: 4024-4031, 1999.
16. Makino Y, Hosoda H, Shibata K, Makino I, Kojima M, Kangawa K, Kawarabayashi T. Alteration of plasma ghrelin levels associated with the blood pressure in pregnancy. Hypertension 39: 781-784, 2002.
17. Malinski T, Kapturczak M, Dayharsh J, Bohr D. Nitric oxide synthase activity in genetic hypertension. Biochem Biophys Res Commun 194: 654-658, 1993.
18. Matsuoka H, Nakata M, Kohno K, Koga Y, Nomura G, Toshima H, Imaizumi T. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 27: 14-18, 1996.
19. McLarty JL, Melendez GC, Brower GL, Janicki JS, Levick SP. Tryptase/orotease-activated receptor 2 interactions induce selective mitogen-activated protein kinase signaling and collagen synthesis by cardiac fibroblasts. Hypertension 58: 264-270, 2011.
20. Moreno M, Chaves JF, Sancho-Bru P, Ramalho F, Ramalho LN, Mansego ML, Ivorra C, Dominguez M, Conde L, Millan C, Mari M, Colmenero J, Lozano JJ, Jares P, Vidal J, Forns X, Arroyo V, Caballeria J, Gines P, Bataller R. Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology 51: 974-985, 2010.
21. Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, Ueno K, Kitakaze M, Miyatake K, Kangawa K. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 110: 3674-3679, 2004.
22. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
23. Pang J, Xu Q, Xu X, Yin H, Xu R, Guo S, Hao W, Wang L, Chen C, Cao JM. Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. Peptides 31: 630-638, 2010.
24. Roeb E, Schleinkofer K, Kernebeck T, Potsch S, Jansen B, Behrmann I, Matern S, Grotzinger J. The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem 277: 50326-50332, 2002.
25. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 16: 1031-1041, 1998.
26. Rossoni G, Locatelli V, Gennaro Colonna V, Muller EE, Berti F. Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium. Pharmacol Res 42: 129-136, 2000.
27. Shah PK. Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med 3: 199-206, 1998.
28. Shinde UA, Desai KM, Yu C, Gopalakrishnan V. Nitric oxide synthase inhibition exaggerates the hypotensive response to ghrelin: role of calcium-activated potassium channels. J Hypertens 23: 779-784, 2005.
29. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 35: 36-44, 2000.
30. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90: 520-530, 2002.
31. Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, Richter U, Fischer JW, Bohm M, Pauschinger M, Schultheiss HP, Tschope C. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 103: 319-327, 2008.
32. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 84: 476-482, 2000.
33. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C, Gil MJ, Monreal I, Diez J. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 17: 107-114, 1999.
34. Wang X, Lv L, Chen Y, Chen J. A CD36 synthetic peptide inhibits silica-induced lung fibrosis in the mice. Toxicol Ind Health 26: 47-53, 2010.
35. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13: 1637-1652, 1989.
36. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 27: 341-348, 1993.
37. Xu X, Jhun BS, Ha CH, Jin ZG. Molecular mechanisms of ghrelinmediated endothelial nitric oxide synthase activation. Endocrinology 149: 4183-4192, 2008.
38. Xu X, Pang J, Yin H, Li M, Hao W, Chen C, Cao JM. Hexarelin suppresses cardiac fibroblast proliferation and collagen synthesis in rat. Am J Physiol Heart Circ Physiol 293: H2952-H2958, 2007.
39. Xu XB, Pang JJ, Cao JM, Ni C, Xu RK, Peng XZ, Yu XX, Guo S, Chen MC, Chen C. GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure. Am J Physiol Heart Circ Physiol 289: H1643-H1651, 2005.
40. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, Miwa T, Sugawara M, Yamaguchi Y, Ookawara T, Suzuki K, Hori M. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 55: 76-82, 2002.
41. Yang CM, Kandaswamy V, Young D, Sen S. Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc Res 36: 236-245, 1997.
42. Yang YL, Lin SH, Chuang LY, Guh JY, Liao TN, Lee TC, Chang WT, Chang FR, Hung MY, Chiang TA, Hung CY. CD36 is a novel and potential anti-fibrogenic target in albumin-induced renal proximal tubule fibrosis. J Cell Biochem 101: 735-744, 2007.
43. 1/Smad 7 expression in the spontaneously hypertensive rats. Eur J Pharmacol 587: 196-203, 2008.